These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 30407241

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
    Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S.
    Eur J Radiol; 2017 May 01; 90():34-41. PubMed ID: 28583645
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y.
    World J Gastroenterol; 2012 Oct 28; 18(40):5753-8. PubMed ID: 23155317
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Perl RM, Portugall J, Hinterleitner C, Hinterleitner M, Kloth C, Walter SS, Bitzer M, Horger MS.
    Anticancer Res; 2021 Mar 28; 41(3):1451-1458. PubMed ID: 33788737
    [Abstract] [Full Text] [Related]

  • 12. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
    Nakamura Y, Kawaoka T, Higaki T, Fukumoto W, Honda Y, Iida M, Fujioka C, Kiguchi M, Aikata H, Chayama K, Awai K.
    Eur J Radiol; 2018 Jan 28; 98():41-49. PubMed ID: 29279169
    [Abstract] [Full Text] [Related]

  • 13. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 28; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 14. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.
    Ippolito D, Sironi S, Pozzi M, Antolini L, Ratti L, Alberzoni C, Leone EB, Meloni F, Valsecchi MG, Fazio F.
    Acad Radiol; 2008 Jul 28; 15(7):919-27. PubMed ID: 18572129
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Jul 28; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Sacco R, Faggioni L, Bargellini I, Ginanni B, Battaglia V, Romano A, Bertini M, Bresci G, Bartolozzi C.
    Dig Liver Dis; 2013 Sep 28; 45(9):776-81. PubMed ID: 23578581
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 28; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 20. Multiphasic Dynamic Computed Tomography Evaluation of Liver Tissue Perfusion Characteristics Using the Dual Maximum Slope Model in Patients With Cirrhosis and Hepatocellular Carcinoma: A Feasibility Study.
    Lee DH, Lee JM, Klotz E, Han JK.
    Invest Radiol; 2016 Jul 28; 51(7):430-4. PubMed ID: 26756941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.